Connect Biopharma (CNTB) News Today $1.62 +0.06 (+3.53%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTB Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Significant Decline in Short InterestSeptember 14 at 6:33 AM | marketbeat.comConnect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Significant Increase in Short InterestSeptember 6, 2025 | marketbeat.comConnect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Increase in Short InterestSeptember 6, 2025 | americanbankingnews.comConnect Biopharma Announces Two Presentations at the European Respiratory Society (ERS) Congress 2025September 4, 2025 | globenewswire.comConnect Biopharma Completes Termination of its American Depositary Receipt Program and Directly Lists its Ordinary Shares on NasdaqSeptember 3, 2025 | globenewswire.comConnect Biopharma (CNTB) Expected to Announce Quarterly Earnings on FridayAugust 31, 2025 | marketbeat.comConnect Biopharma to Present at Two Upcoming Investor Conferences in SeptemberAugust 27, 2025 | globenewswire.comWe're Keeping An Eye On Connect Biopharma Holdings' (NASDAQ:CNTB) Cash Burn RateAugust 26, 2025 | finance.yahoo.comConnect Biopharma (NASDAQ:CNTB) Upgraded to Hold at Wall Street ZenAugust 25, 2025 | marketbeat.comShort Interest in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Drops By 43.9%August 20, 2025 | marketbeat.comQ3 Earnings Estimate for CNTB Issued By Leerink PartnrsAugust 19, 2025 | marketbeat.comQ3 EPS Estimate for Connect Biopharma Lowered by AnalystAugust 17, 2025 | marketbeat.comConnect Biopharma's (CNTB) "Buy" Rating Reaffirmed at HC WainwrightAugust 15, 2025 | marketbeat.comConnect Biopharma Teams with Ickey Woods and the Jovante Woods Foundation to Expand Asthma Education Program NationwideAugust 14, 2025 | globenewswire.comConnect Biopharma Posts Q2 Revenue DropAugust 13, 2025 | theglobeandmail.comConnect Biopharma sees cash runway into 2027August 13, 2025 | msn.comConnect Biopharma reports Q2 EPS (23c) vs. 27c last yearAugust 13, 2025 | msn.comConnect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 13, 2025 | globenewswire.comConnect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Growth in Short InterestAugust 5, 2025 | marketbeat.comWhat is Northland Capmk's Estimate for CNTB Q2 Earnings?July 24, 2025 | marketbeat.comConnect Biopharma (NASDAQ:CNTB) Rating Increased to Strong-Buy at Northland CapmkJuly 23, 2025 | marketbeat.comConnect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of DirectorsJuly 22, 2025 | globenewswire.comConnect Biopharma Shares Rise on Plan to End ADR Program and Directly List on NasdaqJuly 21, 2025 | msn.comConnect Biopharma stock rises after announcing plan to terminate ADR programJuly 21, 2025 | au.investing.comConnect Biopharma Announces Plans to Terminate its American Depositary Receipt Program and Directly List its Ordinary Shares on NasdaqJuly 21, 2025 | globenewswire.comConnect Biopharma to Participate in the BTIG Virtual Biotechnology ConferenceJuly 18, 2025 | globenewswire.comLisa Peraza - CNTB | Connect Biopharma Holdings Ltd. ADR - Wall Street ...July 17, 2025 | wsj.comConnect Biopharma Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 17, 2025 | globenewswire.comConnect Biopharma’s Exclusive Licensee in China, Simcere ...July 11, 2025 | morningstar.comMCNTB Stock Quote Price and Forecast | CNN - CNN InternationalJuly 11, 2025 | edition.cnn.comConnect announces Chinese collaborator submitted NDA for rademikibartJuly 9, 2025 | msn.comConnect Biopharma (NASDAQ:CNTB) Trading Down 2.5% - Here's What HappenedJuly 8, 2025 | marketbeat.comConnect Biopharma Holdings Limited (CNTB) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comCNTB Connect Biopharma Holdings Limited - Seeking AlphaJuly 2, 2025 | seekingalpha.comQ2 Earnings Forecast for CNTB Issued By HC WainwrightJune 16, 2025 | marketbeat.comConnect Biopharma Reports Positive Clinical Results for Rademikibart in Eosinophilic-Driven Type 2 Asthma PatientsJune 15, 2025 | nasdaq.comConnect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual CongressJune 13, 2025 | globenewswire.comConnect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual CongressJune 3, 2025 | globenewswire.comConnect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International ConferenceMay 20, 2025 | globenewswire.comConnect Biopharma Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | globenewswire.comConnect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPDMay 14, 2025 | globenewswire.comConnect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in AsthmaMay 13, 2025 | globenewswire.comConnect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International ConferenceApril 24, 2025 | globenewswire.comBullfrog AI and Connect Biopharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVApril 11, 2025 | markets.businessinsider.comConnect Biopharma announces feedback from FDA Type C meeting for RademikibartApril 2, 2025 | markets.businessinsider.comConnect Biopharma publishes results from rademikibart trialApril 1, 2025 | markets.businessinsider.comConnect Biopharma Announces Positive Type C Meeting with the FDA for RademikibartApril 1, 2025 | globenewswire.comConnect Biopharma reports FY24 (28c) vs ($1.13) last yearMarch 31, 2025 | markets.businessinsider.comConnect Biopharma Announces Publication of Positive Data from Global Phase 2 Trial of Rademikibart in Patients with Moderate-to-Severe Uncontrolled AsthmaMarch 31, 2025 | globenewswire.comConnect Biopharma Reports 2024 Full-Year Financial Results and Provides Business UpdateMarch 31, 2025 | globenewswire.com Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNTB Media Mentions By Week CNTB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTB News Sentiment▼0.990.94▲Average Medical News Sentiment CNTB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTB Articles This Week▼41▲CNTB Articles Average Week Get the Latest News and Ratings for CNTB and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Connect Biopharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PRTC News Today ADCT News Today FULC News Today YMAB News Today ZYBT News Today AUTL News Today DMAC News Today MBX News Today BNTC News Today CTMX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTB) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNTB Stock Alerts